Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jiangxi Jiangzhong Pharmaceutical Enters Distribution Business

This article was originally published in PharmAsia News

Executive Summary

Jiangxi Jiangzhong Pharmaceutical, China's leading OTC drug company, will acquire stakes in Jointown Group's subsidiary Jiangxi Jointown Pharmaceutical with 11.18 million yuan (1.62 million). At the same time, it will pump in 18.8 million yuan ($2.73 million) to increase its equity in Jiangxi Jointown, securing 51 percent of the firm in total. Analysts say the move will expand the marketshare of Jiangzhong Pharmaceutical's brand and products to gain a dominant position in Jiangxi. Jointown can bring complementary products into the region and develop its end-user market through the collaboration. Observers note the trend of pharmaceutical companies entering drug distribution to control the end-user retail market will have significant impact on the domestic industry. (Click here for more - Chinese Language)

You may also be interested in...



What Justice Ginsburg’s Death Means For Pharma

A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.

‘Wrong Move’: Gottlieb Blasts Azar’s Perceived Regulatory Power Play Over FDA; HHS On Defense

The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel